Orbis Medicine is pioneering a new era in oral macrocycle drug discovery through its innovative nGen platform, which systematically explores macrocycle chemical space. This platform enables the rapid generation and testing of a vast library of macrocyclic compounds, referred to as nCycles, optimized for oral bioavailability and membrane permeability. By leveraging high-throughput chemical synthesis and large-scale assaying, Orbis aims to deliver oral alternatives to existing biologic drugs, targeting both intra- and extracellular sites. The company’s approach addresses long-standing challenges in macrocycle drug design, allowing for the exploration of a wide range of therapeutic areas and molecular targets.

The nGen platform is distinguished by its integration of machine learning and automation, which enhances the efficiency of candidate design and accelerates the drug development process. With a starting library of nearly 100 billion compounds, Orbis can generate up to 100,000 unique nCycle candidates in a single design-make-test-analyze cycle. This capability not only de-risks the development of new drugs but also provides a rich data footprint that informs future designs. The combination of advanced chemistry expertise and innovative technology positions Orbis Medicine as a leader in the field, with the potential to significantly expand treatment options for patients across various diseases.

Switzerland

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces its launch with a €26 million financing led by global life sciences investor Novo. The company is focused on macrocycle drugs, described as a family of compounds with a platform to discover, develop.

Orbis Medicine

Company Details